Izotropic ernennt Dr. John McGraw als Vorstandsvorsitzenden
Vancouver, British Columbia--(Newsfile Corp. - Dienstag, 16. März 2021) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic"), ein Unternehmen, das hochauflösende 360°-3D-Brust-CT-Bildgebungstechnologie für die frühere Erkennung und Diagnose von Brustkrebs entwickelt, gibt bekannt, dass sein Verwaltungsrat zum 5. April 2021 Dr. John McGraw zum Vorstandsvorsitzenden ernannt hat. Dr. McGraw hatte zuvor bei Izotropic die Position des Executive Vice President, Commercial...
2021-03-16 9:28 AM EDT
Izotropic Appoints Dr. John McGraw as Chief Executive Officer
Vancouver, British Columbia--(Newsfile Corp. - March 15, 2021) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic"), a company developing 360-degree, high-resolution 3D dedicated breast CT imaging technology for the earlier detection and diagnosis of breast cancers, announces that its Board of Directors has appointed Dr. John McGraw as Chief Executive Officer, effective April 5, 2021. Dr. McGraw previously held the position of Executive Vice President of Commercial...
2021-03-15 8:00 AM EDT
Erste Versicherungsabrechnungscodes für dedizierte Brust-CT in den USA ausgegeben
Vancouver, British Columbia--(Newsfile Corp. - Donnerstag, 4. März 2021) - Izotropic Corporation ("Izotropic") (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), ein Unternehmen, das hochauflösende 3D-Brust-CT-Bildgebungstechnologie für die frühere Erkennung, Diagnose und Behandlung von Brustkrebs entwickelt, freut sich, dass die American Medical Association (AMA) sechs CPT-Abrechnungscodes der Kategorie III für die Brust-CT-Technologie ausgegeben hat. Die Herausgabe dieser ersten...
2021-03-04 10:35 AM EST
Initial Insurance Billing Codes Issued for Dedicated Breast CT in The USA
Vancouver, British Columbia--(Newsfile Corp. - March 4, 2021) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic"), a company developing high-resolution 3D dedicated breast CT imaging technology for the earlier detection, diagnosis, and treatment of breast cancers, is pleased that the American Medical Association (AMA) has released six Category III CPT billing codes for Breast CT technology. The AMA issuance of these initial insurance billing codes spotlights dedicated...
2021-03-04 9:00 AM EST
Izotropic präsentiert neue Website und Unternehmenspräsentation
Vancouver, British Columbia--(Newsfile Corp. - Freitag, 19. Februar 2021) - Izotropic Corporation ("Izotropic" oder das "Unternehmen") (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) vermarktet echte, dedizierte 3D-Brust-CT-Bildgebungstechnologie für die frühere Erkennung, Diagnose und Behandlung von Brustkrebs. Das Unternehmen freut sich bekannt zu geben, dass es eine aktualisierte Website (www.izocorp.com) live geschaltet hat, die einen erweiterten Abschnitt für Investor*innen und eine neue,...
2021-02-19 10:53 AM EST
Izotropic Launches New Website and Corporate Presentation
Vancouver, British Columbia--(Newsfile Corp. - February 19, 2021) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a company commercializing true 3D, dedicated breast CT imaging technology for the earlier detection, diagnosis, and treatment of breast cancers, is pleased to announce it has launched an updated website (www.izocorp.com), which includes an enhanced investor section and a new, comprehensive corporate presentation...
2021-02-19 8:00 AM EST
Izotropic Stellt "Izoview"-Branding Für Seine in Der Entwicklung Befindliche Brust-CT-Plattform Vor Und Beantragt Handelsmarken
Vancouver, British Columbia--(Newsfile Corp. - Dienstag, 9. Februar 2021) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" oder das "Unternehmen"), ein Unternehmen, das echte 3D-Brust-CT-Bildgebungstechnologie für die Früherkennung, Diagnose und Behandlung von Brustkrebs vermarktet, freut sich, seine mit Spannung erwartete Brust-CT-Plattform izoview vorzustellen.
2021-02-09 4:14 PM EST
Izotropic Unveils "Izoview" Branding for Breast CT Platform in Development and Files Trademark Applications
Vancouver, British Columbia--(Newsfile Corp. - February 9, 2021) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a company commercializing true 3D, dedicated breast CT imaging technology for the earlier detection, diagnosis and treatment of breast cancers, is pleased to unveil its highly anticipated breast CT platform, the izoview.
2021-02-09 8:00 AM EST
Izotropic Announces Upgrade to OTCQB Venture Market
Vancouver, British Columbia--(Newsfile Corp. - February 3, 2021) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a company commercializing true 3D, dedicated breast CT imaging technology for the earlier detection, diagnosis and treatment of breast cancers, is pleased to announce it has upgraded its U.S. listing to the OTCQB Venture Market (OTCQB), effective at the opening of trading today, February 3, 2021. "Upgrading to the OTCQB is a milestone...
2021-02-03 8:00 AM EST
3D-CT-Bildgebungsexperte Neues Beiratsmitglied Bei Izotropic
Vancouver, British Columbia--(Newsfile Corp. - Donnerstag, 7. Januar 2021) - Die Izotropic Corporation (CSE: IZO) (OTC Pink: IZOZF) (FSE: 1R3) ("Izotropic" oder das "Unternehmen") freut sich, die Aufnahme von Dr. Jeff Siewerdsen in den wissenschaftlichen Beirat des Unternehmens bekannt zu geben. Der Beirat setzt sich aus Branchenexpert/innen und Autoritäten auf ihren jeweiligen Gebieten zusammen. Dr. Siewerdsen ist Professor und stellvertretender Vorsitzender der Abteilung für Biomedizinische...
2021-01-07 1:08 PM EST
3D CT Imaging Expert Joins Izotropic Advisory
Vancouver, British Columbia--(Newsfile Corp. - January 7, 2021) - Izotropic Corporation (CSE: IZO) (OTC Pink: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company") is pleased to announce the addition of Jeff Siewerdsen Ph.D. to the Company's Scientific Advisory Board, comprised of industry experts and authorities in their respective fields. Dr. Siewerdsen is a Professor and Vice-Chair in the Department of Biomedical Engineering at Johns Hopkins University in Baltimore, with appointments in...
2021-01-07 9:00 AM EST
Izotropic Steht in Den Startlöchern Für 2021
Vancouver, British Columbia--(Newsfile Corp. - Mittwoch, 6. Januar 2021) - Izotropic Corporation (CSE: IZO) (OTC Pink: IZOZF) (FSE: 1R3) ("Izotropic" oder das "Unternehmen") freut sich, ein Update zum Fortschritt seiner Unternehmensgründung und Kommerzialisierung sowie seiner Positionierung für das Jahr 2021 zu geben. Izotropic erreichte 2020 wichtige Meilensteine und erweiterte sein Team um erfahrene Führungskräfte und wichtige Vordenker aus dem Bereich Medizinprodukte. Zusammen leisten wir...
2021-01-06 10:01 AM EST
Izotropic Positioned to Execute in 2021
Vancouver, British Columbia--(Newsfile Corp. - January 5, 2021) - Izotropic Corporation (CSE: IZO) (OTC Pink: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company") is pleased to provide an update on corporate and commercialization progress and its positioning for 2021. Izotropic achieved important milestones in 2020 and added experienced medical device executives and key thought leaders in the medical device sector to its team that continue to provide valuable contributions to product development,...
2021-01-05 9:00 AM EST
Izotropic Reports High Degree of Confidence After Pre-Submission Meeting with FDA
Vancouver, British Columbia--(Newsfile Corp. - December 15, 2020) - Izotropic Corporation (CSE: IZO) (OTC Pink: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company") announces it has received the finalized meeting minutes from the U.S. Food and Drug Administration (FDA) in connection with the Company's recent pre-submission meeting and the market approval process for its commercial Breast CT Imaging System. Dr. John McGraw, Executive Vice-President of Commercial Operations, stated, "I am pleased...
2020-12-15 8:00 AM EST
Izotropic Corporation Announces Closing of Second Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - October 30, 2020) - Izotropic Corporation (CSE: IZO) (OTC Pink: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company") - Further to the Company's News Release of October 20, 2020, the Company is pleased to announce that it has completed the second and final tranche of its non-brokered private placement financing (the "Offering"), whereby the Company issued 2,866,334 units (each, a "Unit") at a price of $0.55 per Unit for gross proceeds of...
2020-10-30 8:00 AM EDT
Izotropic Corporation Announces Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - October 20, 2020) - Izotropic Corporation (CSE: IZO) (OTC Pink: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company") is pleased to announce a non-brokered private placement financing (the "Offering") of up to 6,000,000 units of the Company (each, a "Unit") at a price of $0.55 per Unit for gross proceeds of up to $3,300,000. Each Unit will consist of one common share and one transferable warrant (each, a "Warrant"), and each Warrant will entitle the...
2020-10-20 8:00 AM EDT
Izotropic Announces Meeting Date with FDA
Vancouver, British Columbia--(Newsfile Corp. - September 28, 2020) - Izotropic Corporation (CSE: IZO) (OTC Pink: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company") is pleased to announce that the Company's Executive and Scientific Advisory Teams will meet with the U.S. Food and Drug Administration (FDA) on October 20, 2020. Further to the news release issued August 18, 2020, the Company filed a Pre-Submission Application with the FDA which began the market approval process for the Company's...
2020-09-28 8:00 AM EDT
Mr. Alexander Tokman Joins Izotropic as Strategic Advisor
Vancouver, British Columbia--(Newsfile Corp. - September 15, 2020) - Izotropic Corporation ("Izotropic" or the "Company") (CSE: IZO) (OTC Pink: IZOZF) (FSE: 1R3) is pleased to announce the addition of Mr. Alexander Tokman as Strategic Advisor to the Company's growing advisory board. Mr. Tokman is a growth-driven executive leader with over 22 years of global, cross-functional profit and loss leadership, specializing in creating and commercializing new technology businesses in the Healthcare,...
2020-09-15 8:00 AM EDT
Izotropic Engages MarketSmart Communications
Vancouver, British Columbia--(Newsfile Corp. - August 31, 2020) - Izotropic Corporation (CSE: IZO) (OTC Pink: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company") is pleased to announce it has entered into a consulting agreement with MarketSmart Communications Inc. (MarketSmart) to help build awareness of the company's corporate profile within the investment community. Established in 2002, MarketSmart has represented numerous successful public companies including SONA Nanotech Inc. (Symbol SONA),...
2020-08-31 8:00 AM EDT
Izotropic Files Pre-Submission Application with U.S. FDA
Vancouver, British Columbia--(Newsfile Corp. - August 18, 2020) - Izotropic Corporation (CSE: IZO) (OTC Pink: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company") is pleased to announce that it has filed a Pre-Submission Application with the U.S. Food and Drug Administration (FDA) marking the beginning of the market approval process for the Company's commercial Breast CT Imaging System. The Pre-Submission Application filing has been a highly anticipated event for the Company and is a major...
2020-08-18 8:00 AM EDT